ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,477.90
0.16%
Dow Jones
39,127.80
0.04%
US Dollar vs MXN
18.3408
1.18%
Brent Oil
84.47
0.34%
Bitcoin
60,989.24
-1.33%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Atossa Therapeutics Inc (ATOS)

  7. Atossa Therapeutics Inc (ATOS) Noticias

ATOS

Atossa Therapeutics (ATOS)

Atossa Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ATOS
FechaHoraFuenteTítuloSímboloCompañía
17/06/202407:30GlobeNewswire Inc.Atossa Set to Join Russell 3000® Index Effective June 28, 2024NASDAQ:ATOSAtossa Therapeutics Inc
05/06/202407:30GlobeNewswire Inc.Atossa to Present at the Sidoti Small-Cap Investor ConferenceNASDAQ:ATOSAtossa Therapeutics Inc
28/05/202407:30GlobeNewswire Inc.Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment ModelNASDAQ:ATOSAtossa Therapeutics Inc
23/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATOSAtossa Therapeutics Inc
23/05/202408:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ATOSAtossa Therapeutics Inc
15/05/202407:30GlobeNewswire Inc.Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
14/05/202415:46Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:ATOSAtossa Therapeutics Inc
13/05/202415:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATOSAtossa Therapeutics Inc
13/05/202408:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATOSAtossa Therapeutics Inc
13/05/202408:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
13/05/202407:50GlobeNewswire Inc.Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
10/05/202408:04Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ATOSAtossa Therapeutics Inc
10/05/202408:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ATOSAtossa Therapeutics Inc
07/05/202407:30GlobeNewswire Inc.Atossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesNASDAQ:ATOSAtossa Therapeutics Inc
29/04/202407:30GlobeNewswire Inc.Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-EndoxifenNASDAQ:ATOSAtossa Therapeutics Inc
15/04/202407:30GlobeNewswire Inc.Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
11/04/202407:30GlobeNewswire Inc.Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare ConferenceNASDAQ:ATOSAtossa Therapeutics Inc
09/04/202410:59GlobeNewswire Inc.Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-EndoxifenNASDAQ:ATOSAtossa Therapeutics Inc
01/04/202415:00GlobeNewswire Inc.Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
19/03/202407:30GlobeNewswire Inc.Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer PatientNASDAQ:ATOSAtossa Therapeutics Inc
18/03/202407:30GlobeNewswire Inc.Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementsNASDAQ:ATOSAtossa Therapeutics Inc
12/03/202407:30GlobeNewswire Inc.Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of DirectorsNASDAQ:ATOSAtossa Therapeutics Inc
22/02/202407:30GlobeNewswire Inc.Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS StudyNASDAQ:ATOSAtossa Therapeutics Inc
07/02/202407:30GlobeNewswire Inc.Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
09/01/202407:30GlobeNewswire Inc.Atossa Therapeutics Issues Letter to ShareholdersNASDAQ:ATOSAtossa Therapeutics Inc
04/12/202307:30GlobeNewswire Inc.Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical DirectorNASDAQ:ATOSAtossa Therapeutics Inc
20/11/202307:30GlobeNewswire Inc.Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
15/11/202316:03Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ATOSAtossa Therapeutics Inc
15/11/202315:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATOSAtossa Therapeutics Inc
15/11/202315:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATOSAtossa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATOS

Su Consulta Reciente

AMEX
XLE
Energy Select Sector SPDR
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
NKE
Nike
NYSE
JPM
JP Morgan Chase
CCOM
OILBRENT
Brent Oil
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
CCOM
SILVER
SILVER
AMEX
XLV
Health Care Select Sector
FX
EURUSD
Euro vs US Dollar
COIN
BTCUSD
Bitcoin
COIN
ETHUSD
Ethereum
USOTC
RHHBY
Roche (QX)
NYSE
VZ
Verizon Communications
NYSE
BAC
Bank of America
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados